US20040029173A1 - Protein activity screening of clones having DNA from uncultivated microorganisms - Google Patents
Protein activity screening of clones having DNA from uncultivated microorganisms Download PDFInfo
- Publication number
- US20040029173A1 US20040029173A1 US10/374,576 US37457603A US2004029173A1 US 20040029173 A1 US20040029173 A1 US 20040029173A1 US 37457603 A US37457603 A US 37457603A US 2004029173 A1 US2004029173 A1 US 2004029173A1
- Authority
- US
- United States
- Prior art keywords
- dna
- cell
- cdna
- genomic dna
- dna fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C(NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC(=O)C=C2C(F)(F)F.CC1=CC=CC=C1.CC1=CNC2=C1C=CC=C2.CCCNC(N)=[NH2+] Chemical compound *C(NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC(=O)C=C2C(F)(F)F.CC1=CC=CC=C1.CC1=CNC2=C1C=CC=C2.CCCNC(N)=[NH2+] 0.000 description 1
- DWZSIFSSLKPTPM-UHFFFAOYSA-N CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CC(=O)OCC1=CC=CC=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CC(=O)OCC1=CC=CC=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 DWZSIFSSLKPTPM-UHFFFAOYSA-N 0.000 description 1
- ULPCUMHYLNFYJO-HADILQTOSA-N CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 ULPCUMHYLNFYJO-HADILQTOSA-N 0.000 description 1
- WDVDOUUPQCMSJH-DWEHOVEISA-N CC(=O)OCC1=CC=CC=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)OCC1=CC=CC=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 WDVDOUUPQCMSJH-DWEHOVEISA-N 0.000 description 1
- VMAQYKGITHDWKL-UHFFFAOYSA-N CC(C(N1)=O)NC1=O Chemical compound CC(C(N1)=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 description 1
- FQGVVDYNRHNTCK-UHFFFAOYSA-N CC(C(OC)=O)NC(C)=O Chemical compound CC(C(OC)=O)NC(C)=O FQGVVDYNRHNTCK-UHFFFAOYSA-N 0.000 description 1
- FJLSPBUIBICTEH-UHFFFAOYSA-N CC(N)C(N)=O.NC(=O)C(N)CC1=CC=CC=C1 Chemical compound CC(N)C(N)=O.NC(=O)C(N)CC1=CC=CC=C1 FJLSPBUIBICTEH-UHFFFAOYSA-N 0.000 description 1
- HZGMSCCFRVGETM-UHFFFAOYSA-N CC(NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(NC(CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound CC(NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(NC(CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 HZGMSCCFRVGETM-UHFFFAOYSA-N 0.000 description 1
- IKGHIFGXPVLPFD-UHFFFAOYSA-N CC(NC(Cc1ccccc1)C(OC)=O)=O Chemical compound CC(NC(Cc1ccccc1)C(OC)=O)=O IKGHIFGXPVLPFD-UHFFFAOYSA-N 0.000 description 1
- HXVZGASCDAGAPS-UHFFFAOYSA-N CC(Oc(cc1)cc(O2)c1C(C)=CC2=O)=O Chemical compound CC(Oc(cc1)cc(O2)c1C(C)=CC2=O)=O HXVZGASCDAGAPS-UHFFFAOYSA-N 0.000 description 1
- MUMAHEBVYSIROC-UHFFFAOYSA-N CC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CC1=CC=C2C(C)=CC(=O)OC2=C1 MUMAHEBVYSIROC-UHFFFAOYSA-N 0.000 description 1
- HXHYGDOPYNBZMY-UHFFFAOYSA-N CC1C2CCC(C2)C1COC(=O)C1=CC=CC=C1.O=C(O)C1=CC=CC=C1 Chemical compound CC1C2CCC(C2)C1COC(=O)C1=CC=CC=C1.O=C(O)C1=CC=CC=C1 HXHYGDOPYNBZMY-UHFFFAOYSA-N 0.000 description 1
- FOLIJQAUQJQWOQ-UHFFFAOYSA-N CC1NC(=O)NC1=O.O=C1NC(=O)C(CC2=CC=CC=C2)N1 Chemical compound CC1NC(=O)NC1=O.O=C1NC(=O)C(CC2=CC=CC=C2)N1 FOLIJQAUQJQWOQ-UHFFFAOYSA-N 0.000 description 1
- QNLBHGSBIICKJB-RKKUYNIKSA-N CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 QNLBHGSBIICKJB-RKKUYNIKSA-N 0.000 description 1
- PTKDIBUNVYIPOD-UHFFFAOYSA-N CCC(C)C(=O)OCC1=CC=CC=C1 Chemical compound CCC(C)C(=O)OCC1=CC=CC=C1 PTKDIBUNVYIPOD-UHFFFAOYSA-N 0.000 description 1
- LSLWNAOQPPLHSW-UHFFFAOYSA-N CCC(C)OC(=O)C1=CC=CC=C1 Chemical compound CCC(C)OC(=O)C1=CC=CC=C1 LSLWNAOQPPLHSW-UHFFFAOYSA-N 0.000 description 1
- AGXRFXONBKYHJW-UHFFFAOYSA-P CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)CC2=C1.NC(=[NH2+])NCCC(NC(=O)OC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC1=C(C=CC(NC(=O)C(CCNC(N)=[NH2+])NC(=O)OC3=CC=CC=C3)=C1)C21OC(=O)C2=CC=CC=C21 Chemical compound CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)CC2=C1.NC(=[NH2+])NCCC(NC(=O)OC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC1=C(C=CC(NC(=O)C(CCNC(N)=[NH2+])NC(=O)OC3=CC=CC=C3)=C1)C21OC(=O)C2=CC=CC=C21 AGXRFXONBKYHJW-UHFFFAOYSA-P 0.000 description 1
- REHXHVWLCHFADW-KGNJMLJYSA-N CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 REHXHVWLCHFADW-KGNJMLJYSA-N 0.000 description 1
- OQIQLHLCCRJNIR-BRQGBYBTSA-N CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 Chemical compound CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 OQIQLHLCCRJNIR-BRQGBYBTSA-N 0.000 description 1
- NKQFKJYKCVDLPT-KHPPLWFESA-N CCCCCCCC/C=C\CCCCCCCC(Oc1ccc(C(C)=CC(O2)=O)c2c1)=O Chemical compound CCCCCCCC/C=C\CCCCCCCC(Oc1ccc(C(C)=CC(O2)=O)c2c1)=O NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- ONKDNNHPWYZAOS-GMFCBQQYSA-N CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 Chemical compound CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 ONKDNNHPWYZAOS-GMFCBQQYSA-N 0.000 description 1
- FWRQUMDONRWNOY-RVVQQURLSA-N CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1.CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 Chemical compound CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1.CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 FWRQUMDONRWNOY-RVVQQURLSA-N 0.000 description 1
- QOIJAZYHGUNKLA-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC(Oc1ccc(C(C)=CC(O2)=O)c2c1)=O Chemical compound CCCCCCCCCCCCCCCCCC(Oc1ccc(C(C)=CC(O2)=O)c2c1)=O QOIJAZYHGUNKLA-UHFFFAOYSA-N 0.000 description 1
- JYRIRSQSAQVJLC-UHFFFAOYSA-N CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 Chemical compound CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 JYRIRSQSAQVJLC-UHFFFAOYSA-N 0.000 description 1
- VOYQUJHGJRCFCS-UHFFFAOYSA-N COC(=O)C(C)NC(C)=O.COC(=O)C(CC1=CC=CC=C1)NC(C)=O Chemical compound COC(=O)C(C)NC(C)=O.COC(=O)C(CC1=CC=CC=C1)NC(C)=O VOYQUJHGJRCFCS-UHFFFAOYSA-N 0.000 description 1
- DBOMTIHROGSFTI-UHFFFAOYSA-N O=C(C(Cc1ccccc1)N1)NC1=O Chemical compound O=C(C(Cc1ccccc1)N1)NC1=O DBOMTIHROGSFTI-UHFFFAOYSA-N 0.000 description 1
- FCJSHPDYVMKCHI-UHFFFAOYSA-N O=C(OC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=C(OC1=CC=CC=C1)C1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
- NNLZSROCINYYQB-UHFFFAOYSA-N O=C(OC1C=CC(OC(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1 Chemical compound O=C(OC1C=CC(OC(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1 NNLZSROCINYYQB-UHFFFAOYSA-N 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=C(OCC1=CC=CC=C1)C1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- FPRNNCROFFHQRZ-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1C2CCC(C2)C1C(=O)OCC1=CC=CC=C1 Chemical compound O=C(OCC1=CC=CC=C1)C1C2CCC(C2)C1C(=O)OCC1=CC=CC=C1 FPRNNCROFFHQRZ-UHFFFAOYSA-N 0.000 description 1
- XQGBPGPXQBKONU-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1C=CC(C(=O)OOC2=CC=CC=C2)CC1 Chemical compound O=C(OCC1=CC=CC=C1)C1C=CC(C(=O)OOC2=CC=CC=C2)CC1 XQGBPGPXQBKONU-UHFFFAOYSA-N 0.000 description 1
- QTQJGYARTUGFJD-UHFFFAOYSA-N O=C1C=C(C(F)(F)F)C2=CC=C(NC(=O)C(CC3=CC=CC=C3)NC(=O)N3CCOCC3)C=C2O1 Chemical compound O=C1C=C(C(F)(F)F)C2=CC=C(NC(=O)C(CC3=CC=CC=C3)NC(=O)N3CCOCC3)C=C2O1 QTQJGYARTUGFJD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Definitions
- This invention relates to the field of preparing and screening libraries of clones containing microbially derived DNA.
- the invention provides a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity which process comprises:
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- DNA is ligated into a vector, particularly wherein the vector further comprises expression regulatory sequences which can control and regulate the production of a detectable proteins, e.g. enzyme, activity from the ligated DNA.
- a detectable proteins e.g. enzyme
- the f-factor (or fertility factor) in E. cold is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use a cloning vector containing an f-factor origin of replication to generate genomic libraries that can be replicated with a high degree of fidelity. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- double stranded DNA obtained from the uncultivated DNA population is selected by:
- the probe may be directly or indirectly bound to a solid phase by which it is separated from single stranded DNA which is not hybridized or otherwise specifically bound to the probe.
- the process can also include releasing single stranded DNA from said probe after recovering said hybridized or otherwise bound single stranded DNA and amplifying the single stranded DNA so released prior to converting it to double stranded DNA.
- the invention also provides a process of screening clones having DNA from an uncultivated microorganisms for a specified protein, e.g. enzyme, activity which comprises screening for a specified gene cluster protein product activity in the library of clones prepared by: (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii3 transforming a host with recovered DNA to produce a library of clones with the screens for the specified protein, e.g. enzyme, activity.
- the library is produced from gene cluster DNA which is recovered without culturing of an organism, particularly where the DNA gene clusters are recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- double-stranded gene cluster DNA obtained from the uncultivated DNA population is selected by converting the double-stranded genomic gene cluster DNA into single-stranded DNA; recovering from the converted single-stranded gene cluster polycistron DNA, single-stranded DNA which specifically binds, such as by hybridization, to a polynucleotide probe sequence; and converting recovered single-stranded gene cluster DNA to double-stranded DNA.
- the microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archacbacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
- the microorganisms are uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles, psychrotrophs, etc.
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- Sources of microorganism DNA as a starting material library from which DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
- genomic DNA may be recovered from either uncultured or non-culturable organism and employed to produce an appropriate library of clones for subsequent determination of protein, e.g. enzyme, activity.
- genes Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
- the genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
- the gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes, usually from 2 to 6 genes.
- a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
- gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including proteins, e.g. enzymes, such as, for example, the polyketide syntheses that are responsible for the synthesis of polyketides having a vast array of useful activities.
- proteins e.g. enzymes, such as, for example, the polyketide syntheses that are responsible for the synthesis of polyketides having a vast array of useful activities.
- Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide syntheses) are valuable as therapeutic agents. Polyketide syntheses are multifunctional proteins, e.g. enzymes, that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide syntheses have large size genes and proteins, e.g. enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins.
- the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli .
- This f-factor of E. cold is a plasmid which affect high frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- derived or “isolated” means that material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- the DNA isolated or derived from these microorganisms can preferably be inserted into a vector prior to probing for selected DNA.
- Such vectors are preferably those containing expression regulatory sequences, including promoters, enhancers and the like.
- Such polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmid and methods for introduction and packaging into them are described in detail in the protocol set forth herein.
- the probe DNA used for selectively recovering DNA of interest from the DNA derived from the at least one uncultured microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an protein, e.g. enzyme, of known activity, a phylogenetic marker or other identified DNA sequence.
- the original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding the specified activity.
- These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form.
- the probes that are particularly suitable are those derived from DNA encoding proteins, e.g. enzymes, having an activity similar or identical to the specified protein, e.g. enzyme, activity which is to be screened.
- the probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source.
- the ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) a protein, e.g. enzyme, and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor.
- the solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- the library of clones prepared as described above can be screened directly for enzymatic activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.
- the selectively isolated DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts.
- the double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- the selected DNA is then used for preparing a library for screening by transforming a suitable organism.
- Hosts particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- the resultant libraries of transformed clones are then screened for clones which display activity for the protein, e.g. enzyme, of interest in a phenotypic assay for protein, e.g. enzyme, activity.
- the screening for protein, e.g. enzyme, activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified protein, e.g. enzyme, activities. If the mixture has a specified protein, e.g. enzyme, activity, then the individual clones may be rescreened for such protein, e.g. enzyme, activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- the DNA derived from a microorganism(s) is preferably inserted into an appropriate vector (generally a vector containing suitable regulatory sequences for effecting expression) prior to subjecting such DNA to a selection procedure to select and isolate therefrom DNA which hybridizes to DNA derived from DNA encoding an proteins, e.g. enzyme(s), having the specified protein, e.g. enzyme, activity.
- an appropriate vector generally a vector containing suitable regulatory sequences for effecting expression
- expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, phosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.)
- the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide.
- Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBLUESCRIPT SK, pBLUESCRIPT KS (Stratagene); pTRC99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pWLNEO, pXTI, pSG5 (Stratagene) pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
- a particularly preferred type of vector for use in the present invention contains an f-factor origin of replication.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from the E. cold f-factor and are able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- the DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoter particularly named bacterial promoters include lac, lacZ, T3, T7, apt, lambda PR, PL and trp.
- Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40. LTRs from retrovirus, and mouse metallotnionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- the expression vector also contains a ribosome-binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g. the ampicillin resistance gene of E. cold and S. cerevisiae TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence.
- promoters can be derived from operons encoding glycolytic proteins, e.g. enzymes, such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others.
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired protein, e.g. enzyme, activity.
- the selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an protein, e.g. enzyme, may be expressed, for detection of the desired activity.
- the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by transformation, calcium phosphate transfection, DEAE-Dextran mediated transfection, DMSO or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
- bacterial cells such as E. coli , Bacillus, Streptomyces, Salmonella typhimurium ; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera SJ9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transfonnants or amplifying genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the library may be screened for a specified protein, e.g. enzyme, activity by procedures known in the art.
- the protein, e.g. enzyme, activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, Lyases, isomerases and ligases.
- the recombinant proteins, e.g. enzymes, which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific protein, e.g. enzyme, activity.
- the library may be screened for a more specialized protein, e.g. enzyme, activity.
- the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts.
- the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- the clones which are identified as having the specified protein, e g. enzyme, activity may then be sequenced to identify the DNA sequence encoding an protein, e.g. enzyme, having the specified activity.
- an protein e.g. enzyme
- proteins e.g. enzymes, having such activity (including the amino acid sequence thereof) and (iii) produce recombinant proteins, e.g. enzymes, having such activity.
- the present invention may be employed for example, to identify uncultured microorganisms with proteins, e.g. enzymes, having, for example, the following activities which may be employed for the following uses:
- Adaptor Ligation 1. Gently resuspend DNA in 8 Ill EcoR I adaptors (from Stratagene's cDNA Synthesis Kit). 2. Add: 1.0 ⁇ l 10X Ligation Buffer 1.0 ⁇ l 10 mM rATP 1.0 ⁇ l T4 DNA Ligase (4 Wu/ ⁇ l) 3. Incubate 4° C., 2 days.
- Tier 1 Hydrolase Tier 2: Amide, Ester and Acetal
- Tier 3 Divisions and subdivisions are based upon the differences between individual substrates which are covalently attached to the functionality of Tier 2 undergoing reaction; as well as substrate specificity.
- Tier 4 The two possible enantiomeric products which the protein, e.g. enzyme, may produce from a substrate.
- Tier 1-hydrolase Screening for Tier 1-hydrolase; Tier 2-amide. Plates of the library prepared as described in Example 1 are used to multiply inoculate a single plate containing 200 ⁇ l of LB Amp/Meth, glycerol in each well. This step is performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach, water, isopropanol, air-dry sterilization cycle between each inoculation. The single plate is grown for 2 h at 37° C. and is then used to inoculate two white 96-well Dynatech microtiter daughter plates containing 250 ⁇ l of LB Arnp/Meth, glycerol in each well.
- HDRT High Density Replicating Tool
- the original single plate is incubated at 37° C. for 18 h, then stored at 80° C.
- the two condensed daughter plates are incubated at 37° C. also for 18 h.
- the condensed daughter plates are then heated at 70° C. for 45 min. to kill the cells and inactivate the host E. coli proteins, e.g. enzymes.
- a stock solution of 5 mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl cournarin (MuPheAFC, the ‘substrate’) in DMSO is diluted to 600 ⁇ M with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/ml of the detergent dodecyl maltoside.
- the data will indicate whether one of the clones in a particular well is hydrolyzing the substrate.
- the source library plates are thawed and the individual clones are used to singly inoculate a new plate containing LB Amp/Meth, glycerol.
- the plate is incubated at 37° C. to grow the cells, heated at 70° C. to inactivate the host proteins, e.g. enzymes, and 50 ⁇ l of 600 ⁇ M MuPheAFC is added using the Biomek.
- three other substrates are tested. They are methyl umbelliferone heptanoate, the CBZ-arginine rhodamine derivative, and fluorescein-conjugated casein ( ⁇ 3.2 mol fluorescein per mol of casein).
- the umbelliferone and rhodamine are added as 600 ⁇ M stock solutions in 50 ⁇ l of Hepes buffer.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as amide may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 1 which are used in identifying such specificities of Tier 3.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as ester may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Tables 3 and 4 which are used in identifying such specificities of Tier 3.
- R 2 represents the alcohol portion of the ester and R 1 represents the acid portion of the ester.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as acetal may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 5 which are used in identifying such specificities of Tier 3.
- Proteins e.g. enzymes
- chiral amino esters may be determined using at least the following substrates:
- E ln ⁇ [ 1 - c ⁇ ( 1 + ee p ) ] ln ⁇ [ 1 - c ⁇ ( 1 - ee p ) ]
- the enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred ⁇ l of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 ⁇ l of partially or completely purified protein, e.g. enzyme, solution; 50 ⁇ l of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, whichever comes first.
- HPLC high performance liquid chromatography
- CE chiral capillary electrophoresis
- FIG. 5 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample.
- a stable, large insert DNA library representing picoplankton genomic DNA was prepared as follows.
- the cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40° C., and then immediately drawn into a 1 ml syringe. The syringe was sealed with parafilm and placed on ice for 10 min. The cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10 mM Tris pH 8.0, 50 mM NaCI, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme) and incubated at 37° C. for one hour.
- Lysis Buffer 10 mM Tris pH 8.0, 50 mM NaCI, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme
- the agarose plug was then transferred to 40 mls of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase K, in 0.5M EDTA), and incubated at 55° C. for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55° C. for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4° C. shipboard for the duration of the oceanographic cruise.
- ESP Buffer 1% Sarkosyl, 1 mg/ml proteinase K, in 0.5M EDTA
- the solution was then changed to 250 ⁇ l of the same buffer containing 4U of Sau3A1 (NEB), equilibrated to 37EC in a water bath, and then incubated on a rocking platform in a 37° C. incubator for 45 min.
- the plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68° C. for 30 min to inactivate the protein, e.g. enzyme, and to melt the agarose.
- the agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase (Epicentre), respectively, according to the manufacturer's recommendations.
- Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H 2 0 to a concentration of 2.5 ng/ ⁇ l for ligation to the pFOS 1 vector.
- PCR amplification results from several of the agarose plugs indicated the presence of significant amounts of archaeal DNA.
- Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation.
- Each 1 ml agarose plug from this site contained approximately 7.5 ⁇ 10 5 cells, therefore approximately 5.4 ⁇ 10 5 cells were present in the 72 ⁇ l slice used in the preparation of the partially digested DNA.
- Vector arms were prepared from pFOS 1 as described (Kim et al., Stable propagation of casmid sized human DNA inserts in an F factor based vector, Nucl. Acids Res., 20:10832-10835, 1992). Briefly, the plasmid was completely digested with AstII, dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 35-45 kbp.
- the partially digested picoplankton DNA isolated by partial fragment gel electrophoresis (PFGE) was ligated overnight to the PFO SI arms in a 15 ⁇ l ligation reaction containing 25 ng each of vector and insert and 1U of T4 DNA ligase (Boehringer-Mannheim).
- the ligated DNA in four microliters of this reaction was in vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected to E. coli strain DH10B (BRL), and the cells spread onto LB cm15 plates.
- the resultant fosmid clones were picked into 96-well microliter dishes containing LB cm15 supplemented with 7% glycerol.
- Recombinant fosmids each containing cat 40 kb of picoplankton DNA insert, yielded a library of 3,552 fosmid clones, containing approximately 1.4 ⁇ 10 8 base pairs of cloned DNA. All of the clones examined contained inserts ranging from 38 to 42 kbp. This library was stored frozen at ⁇ 80° C. for later analysis.
Abstract
Disclosed is a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity by screening for a specified protein, e.g. enzyme, activity in a library of clones prepared by (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones which is screened for the specified protein, e.g. enzyme, activity.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 08/568,994 which was filed on Dec. 7, 1995 (copending) which is a continuation-in-part of U.S. application Ser. No. 08/503,606 which was filed on Jul. 18, 1995 (copending).
- This invention relates to the field of preparing and screening libraries of clones containing microbially derived DNA.
- Naturally occurring assemblages of microorganisms often encompass a bewildering array of physiological and metabolic diversity. In fact, it has been estimated that to date less than one percent of the world's organisms have been cultured. It has been suggested that a large fraction of this diversity thus far has been unrecognized due to difficulties in enriching and isolating microorganisms in pure culture. Therefore, it has been difficult or impossible to identify or isolate valuable proteins, e.g. enzymes, from these samples. These limitations suggest the need for alternative approaches to characterize the physiological and metabolic potential, i e. activities of interest of as-yet uncultivated microorganisms, which to date have been characterized solely by analyses of PCR amplified rRNA gene fragments, clonally recovered from mixed assemblage nucleic acids.
- In one aspect, the invention provides a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity which process comprises:
- screening for a specified protein, e.g. enzyme, activity in a library of clones prepared by
- (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and
- (ii) transforming a host with recovered DNA to produce a library of clones which are screened for the specified protein, e.g. enzyme, activity.
- The library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- In a preferred embodiment DNA is ligated into a vector, particularly wherein the vector further comprises expression regulatory sequences which can control and regulate the production of a detectable proteins, e.g. enzyme, activity from the ligated DNA.
- The f-factor (or fertility factor) in E. cold is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. To achieve and stably propagate large DNA fragments from mixed microbial samples, a particularly preferred embodiment is to use a cloning vector containing an f-factor origin of replication to generate genomic libraries that can be replicated with a high degree of fidelity. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- In another preferred embodiment, double stranded DNA obtained from the uncultivated DNA population is selected by:
- converting the double stranded genomic DNA into single stranded DNA;
- recovering from the converted single stranded DNA single stranded DNA which specifically binds, such as by hybridization, to a probe DNA sequence; and
- converting recovered single stranded DNA to double stranded DNA.
- The probe may be directly or indirectly bound to a solid phase by which it is separated from single stranded DNA which is not hybridized or otherwise specifically bound to the probe.
- The process can also include releasing single stranded DNA from said probe after recovering said hybridized or otherwise bound single stranded DNA and amplifying the single stranded DNA so released prior to converting it to double stranded DNA.
- The invention also provides a process of screening clones having DNA from an uncultivated microorganisms for a specified protein, e.g. enzyme, activity which comprises screening for a specified gene cluster protein product activity in the library of clones prepared by: (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii3 transforming a host with recovered DNA to produce a library of clones with the screens for the specified protein, e.g. enzyme, activity. The library is produced from gene cluster DNA which is recovered without culturing of an organism, particularly where the DNA gene clusters are recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- Alternatively, double-stranded gene cluster DNA obtained from the uncultivated DNA population is selected by converting the double-stranded genomic gene cluster DNA into single-stranded DNA; recovering from the converted single-stranded gene cluster polycistron DNA, single-stranded DNA which specifically binds, such as by hybridization, to a polynucleotide probe sequence; and converting recovered single-stranded gene cluster DNA to double-stranded DNA.
- These and other aspects of the present invention are described with respect to particular preferred embodiments and will be apparent to those skilled in the art from the teachings herein.
- The microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archacbacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. The microorganisms are uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles, psychrotrophs, etc.
- As indicated above, the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured. Sources of microorganism DNA as a starting material library from which DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. Thus, for example, genomic DNA may be recovered from either uncultured or non-culturable organism and employed to produce an appropriate library of clones for subsequent determination of protein, e.g. enzyme, activity.
- Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. The gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes, usually from 2 to 6 genes. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
- It is important to further research gene clusters and the extent to which the full length of the cluster is necessary for the expression of the proteins resulting therefrom. Further, gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including proteins, e.g. enzymes, such as, for example, the polyketide syntheses that are responsible for the synthesis of polyketides having a vast array of useful activities. Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide syntheses) are valuable as therapeutic agents. Polyketide syntheses are multifunctional proteins, e.g. enzymes, that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide syntheses have large size genes and proteins, e.g. enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins.
- The ability to select and combine desired components from a library of polyketides and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing. The method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide syntheses, since one can generate gene banks with clones containing large inserts (especially when using the f-factor based vectors), which facilitates cloning of gene clusters.
- Preferably, the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) ofE. coli. This f-factor of E. cold is a plasmid which affect high frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- The term “derived” or “isolated” means that material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- The DNA isolated or derived from these microorganisms can preferably be inserted into a vector prior to probing for selected DNA. Such vectors are preferably those containing expression regulatory sequences, including promoters, enhancers and the like. Such polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmid and methods for introduction and packaging into them are described in detail in the protocol set forth herein.
- The following outlines a general procedure for producing libraries from nonculturable organisms, which libraries can be probed to select therefrom DNA sequences which hybridize to specified probe DNA:
- Obtain Biomass
- DNA Isolation
- Shear DNA (25 gauge needle)
- Blunt DNA (Mung Bean Nuclease)
- Methylate (EcoR I Methylase)
- Ligate to EcoR I linkers (GGAATTCC)
- Cut back linkers (EcoR I Restriction Endonuclease)
- Size Fractionate (Sucrose Gradient)
- Ligate to lambda vector (Lambda ZAP7 (Stratagene) and gtl 1)
- Package (in vitro lambda packaging extract)
- Plate on E. cold host and amplify
- The probe DNA used for selectively recovering DNA of interest from the DNA derived from the at least one uncultured microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an protein, e.g. enzyme, of known activity, a phylogenetic marker or other identified DNA sequence. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding the specified activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding proteins, e.g. enzymes, having an activity similar or identical to the specified protein, e.g. enzyme, activity which is to be screened.
- The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- Preferably the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) a protein, e.g. enzyme, and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- The library of clones prepared as described above can be screened directly for enzymatic activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.
- Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the selectively isolated DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- The resultant libraries of transformed clones are then screened for clones which display activity for the protein, e.g. enzyme, of interest in a phenotypic assay for protein, e.g. enzyme, activity.
- Having prepared a multiplicity of clones from DNA selectively isolated from an organism, such clones are screened for a specific protein, e.g. enzyme, activity and to identify the clones having the specified protein, e.g enzyme, characteristics.
- The screening for protein, e.g. enzyme, activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified protein, e.g. enzyme, activities. If the mixture has a specified protein, e.g. enzyme, activity, then the individual clones may be rescreened for such protein, e.g. enzyme, activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- The DNA derived from a microorganism(s) is preferably inserted into an appropriate vector (generally a vector containing suitable regulatory sequences for effecting expression) prior to subjecting such DNA to a selection procedure to select and isolate therefrom DNA which hybridizes to DNA derived from DNA encoding an proteins, e.g. enzyme(s), having the specified protein, e.g. enzyme, activity.
- As representative examples of expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, phosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.) Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBLUESCRIPT SK, pBLUESCRIPT KS (Stratagene); pTRC99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pWLNEO, pXTI, pSG5 (Stratagene) pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
- A particularly preferred type of vector for use in the present invention contains an f-factor origin of replication. The f-factor (or fertility factor) inE. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. A particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from the E. cold f-factor and are able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- The DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Particular named bacterial promoters include lac, lacZ, T3, T7, apt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40. LTRs from retrovirus, and mouse metallotnionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome-binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance inE. coli.
- Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g. the ampicillin resistance gene of E. cold andS. cerevisiae TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic proteins, e.g. enzymes, such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- The DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired protein, e.g. enzyme, activity. The selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an protein, e.g. enzyme, may be expressed, for detection of the desired activity. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by transformation, calcium phosphate transfection, DEAE-Dextran mediated transfection, DMSO or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
- As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such asE. coli, Bacillus, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera SJ9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc.
- The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transfonnants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- The library may be screened for a specified protein, e.g. enzyme, activity by procedures known in the art. For example, the protein, e.g. enzyme, activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, Lyases, isomerases and ligases. The recombinant proteins, e.g. enzymes, which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific protein, e.g. enzyme, activity.
- Alternatively, the library may be screened for a more specialized protein, e.g. enzyme, activity. For example, instead of generically screening for hydrolase activity, the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- The clones which are identified as having the specified protein, e g. enzyme, activity may then be sequenced to identify the DNA sequence encoding an protein, e.g. enzyme, having the specified activity. Thus, in accordance with the present invention it is possible to isolate and identify: (i) DNA encoding an protein, e.g. enzyme, having a specified protein, e.g. enzyme, activity, (ii) proteins, e.g. enzymes, having such activity (including the amino acid sequence thereof) and (iii) produce recombinant proteins, e.g. enzymes, having such activity.
- The present invention may be employed for example, to identify uncultured microorganisms with proteins, e.g. enzymes, having, for example, the following activities which may be employed for the following uses:
- 1. Lipase/Esterase
- a. Enantioselective hydrolysis of esters (lipids)/thioesters
- 1) Resolution of racemic mixtures
- 2) Synthesis of optically active acids or alcohols from mesodiesters
- b. Selective syntheses
- 1) Regiospecific hydrolysis of carbohydrate esters
- 2) Selective hydrolysis of cyclic secondary alcohols
- c. Synthesis of optically active esters, lactones, acids, alcohols
- 1) Transesterification of activated/nonactivated esters
- 2) Interesterification
- 3) Optically active lactones from hydroxyesters
- 4) Regio- and enantioselective ring opening of anhydrides
- d. Detergents
- e. Fat/Oil conversion
- f. Cheese ripening
- 2. Protease
- a. Ester/amide synthesis
- b. Peptide synthesis
- c. Resolution of racemic mixtures of amino acid esters
- d. Synthesis of non-natural amino acids
- e. Detergents/protein hydrolysis
- 3. Glycosidase/Glycosyl transferase
- a. Sugar/polymer synthesis
- b. Cleavage of glycosidic linkages to form mono, all-and oligosaccharides
- c. Synthesis of complex oligosaccharides
- d. Glycoside synthesis using UDP-galactosyl transferase
- e. Transglycosylation of disaccharides, glycosyl fluorides, aryl galactosides
- f. Glycosyl transfer in oligosaccharide synthesis
- g. Diastereoselective cleavage of p-glucosylsulfoxides
- h. Asymmetric glycosylations
- i. Food processing
- j. Paper processing
- 4. Phosphatase/Kinase
- a. Synthesis/hydrolysis of phosphate esters
- 1) Regio-, enantioselective phosphorylation
- 2) Introduction of phosphate esters
- 3) Synthesize phospholipid precursors
- 4) Controlled polynucleotide synthesis
- b. Activate biological molecule
- c. Selective phosphate bond formation without protecting groups
- 5. Mono/Dioxygenase
- a. Direct oxyfunctionalization of unactivated organic substrates
- b. Hydroxylation of alkanes, aromatics, steroids
- c. Epoxidation of alkenes
- d. Enantioselective sulphoxidation
- e. Regio- and stereoselective Bayer-Villiger oxidation
- 6. Haloperoxidase
- a. Oxidative addition of halide ion to nucleophilic sites
- b. Addition of hypohalous acids to olefinic bonds
- c. Ring cleavage of cyclopropanes
- d. Activated aromatic substrates converted to ortho and para derivatives
- e. 1.3 diketones converted to 2-halo-derivatives
- f. Heteroatom oxidation of sulfur and nitrogen containing substrates
- g. Oxidation of enol acetates, alkynes and activated aromatic rings
- 7. Lignin peroxidase/Diarylpropane peroxidase
- a. Oxidative cleavage of C-C bonds
- b. Oxidation of benzylic alcohols to aldehydes
- c. Hydroxylation of benzylic carbons
- d. Phenol dimerization
- e. Hydroxylation of double bonds to form diols
- f. Cleavage of lignin aldehydes
- 8. Epoxide hydrolase
- a. Synthesis of enantiomerically pure bioactive compounds
- b. Regio- and enantioselective hydrolysis of epoxide Aromatic and olefinic epaxidation by monoaxygenases to form epoxides
- c. Resolution of racemic epoxides
- d. Hydrolysis of steroid epoxides
- 9. Nitrile hydratase/nitriluse
- a. Hydrolysis of aliphatic nitrites to carboxamides
- b. Hydrolysis of aromatic, heterocyclic, unsaturated aliphatic nitrites to corresponding acids
- c. Hydrolysis of acrylonitrile
- d. Production of aromatic and carboxamides, carboxylic acids (nicotinamide, picolinamide, isonicotinamide)
- e. Regioselective hydrolysis of acrylic dinitrile
- f. a-amino acids from a-hydroxynitriles
- 10. Transaminase
- a. Transfer of amino groups into oxo-acids
- 11. Amidase/Acylase
- a. Hydrolysis of amides, amidines, and other C-N bonds
- b. Non-natural amino acid resolution and synthesis
- The following outlines the procedures used to generate a gene library from a sample of the exterior surface of a whale bone found at 1240 meters depth in the Santa Catalina Basin during a dive expedition.
- Isolate DNA.
- ISOQUICK Procedure as per manufacturer's instructions.
- Shear DNA
- 1. Vigorously push and pull DNA through a 25G double-hub needle and 1-cc syringes about 500 times.
- 2. Check a small amount (0.5 μg) on a 0.8% agarose gel to make sure the majority of the DNA is in the desired size range (about 3-6 kb).
- Blunt DNA
- 1. Add:
- H2O to a final volume of 405 μl
- 45 μl 10X Mung Bean Buffer
- 2.0 μl Mung Bean Nuclease (150 μ/μl)
- 2. Incubate 37° C., 15 minutes.
- 3. Phenol/chloroform extract once.
- 4. Chloroform extract once.
- 5. Add 1 ml ice cold ethanol to precipitate.
- 6. Place on ice for 10 minutes.
- 7. Spin in microfuge, high speed, 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry. to a final volume of 4.0 μl
- Methylate DNA
- 1. Gently resuspend DNA in 26 μl TE.
- 2. Add:
- 4.0 μl 10X EcoR I Methylase Buffer
- 0.5 μl SAM (32 mM)
- 5.0 μl EcoR I Methylase (40 μ/μl)
- 3. Incubate 37° C., 1 hour
- Insure Blunt Ends
- 1. Add to the methylation reaction:
- 5.0 μl 100 mM MgCl2
- 8.0 μl dNTP mix (2.5 mM of each dGTP, dATP, dTTP, dCTP)
- 4.0 μl Klenow (5 μ/μl)
- 2. Incubate 12° C., 30 minutes.
- 3. Add 450 μl 1X STE.
- 4. Phenol/chloroform extract once.
- 5. Chloroform extract once.
- 6. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- 7. Spin in microfuge, high speed, 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry.
- Linker Ligation
- 1. Gently resuspend DNA in 7 μl Tris-EDTA (TE).
- 2. Add:
- 14 μl Phosohorylated EcoR I linkers (200 ng/μl)
- 3.0 μl 10X Litigation Buffer
- 3.0 μl 10 mM rATP
- 3.0 μl T4 DNA Ligase (4Wu/μl)
- 3. Incubate 4° C., overnight.
- EcoRI Cutback
- 1. Heat kill ligation reaction 68° C., 10 minutes.
- 2. Add:
- 237.9 μl H2O
- 30 μl 10X EcoR I Buffer
- 2.1 μl EcoR I Restriction Enzyme (100 u/μl)
- 3. Incubate 37° C., 1.5 hours.
- 4. Add 1.5 μl 0.5 M EDTA.
- 5. Place on ice.
- Sucrose Gradient (2.2 ml) Size Fractionation
- 1. Heat sample to 65° C., 10 minutes.
- 2. Gently load on 2.2 ml sucrose gradient.
- 3. Spin in mini-ultracentrifuge, 45K, 20° C., 4 hours (no brake).
- 4. Collect fractions by puncturing the bottom of the gradient tube with a 20G needle and allowing the sucrose to flow through the needle.
- Collect the first 20 drops in a Falcon 2059 tube then collect 10 1-drop fractions (labeled 1-10). Each drop is about 60 μl in volume.
- 5. Run 5 μl of each fraction on a 0.8% agarose gel to check the size.
- 6. Pool fractions 1-4 (−10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb).
- 7. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- 8. Spin in microfuge, high speed, 30 minutes.
- 9. Wash with 1 ml 70% ethanol.
- 10. Spin in microfuge, high speed, 10 minutes and dry.
- 11. Resuspend each in 10 μl TE buffer.
- Test Ligation to Lambda Arms
- 1. Plate assay to get an approximate concentration. Spot 0.5 pl of the sample on agarose containing ethidium bromide along with standards (DNA samples of known concentration). View in UV light and estimate concentration compared to the standards.
-
Fraction 1−4=>1.0 μg/μl 1. Fraction 5−7=500 ng/μl. - 2. Prepare the following ligation reactions (5 pl reactions) and incubate 4° C., overnight:
10 × Lambda T4 DNA Ligase 10 mM arms Insert Ligase Sample H2O Buffer rATP (gt11 and ZAP) DNA (4 Wu/μ) Fraction 0.5 μl 0.5 μl 0.5 μl 1.0 μl 2.0 μl 0.5 μl 1-4 Fraction 0.5 μl 0.5 μl 0.5 μl 1.0 μl 2.0 μl 0.5 μl 5-7 - Test Package and Plate
- 1. Package the ligation reactions following manufacturer's protocol. Package 2.5 μl per packaging extract (2 extracts per ligation).
- 2. Stop packaging reactions with 500 μl SM buffer and pool packaging that came from the same ligation.
- 3. Titer 1.0 μl of each on appropriate host (OD6W=1.0) [XLIBlue MRF for ZAP7 (Stratagene) and Y1088 for gt11]
- Add 200 μl host (in mM MgSO4) to Falcon 2059 tubes
- Inoculate with 1 μl packaged phage
- Incubate 37° C., 15 minutes
- Add about 3 ml 48° C. top agar
- [50 ml stock containing 150 μl IPTG (0.5M) and 300 μl X-GAL (350 mg/ml)]
- Plate on 100 mm plates and incubate 37° C., overnight.
- 4. Efficiency results:
gtll: 1.7 × 104 recombinants with 95% background ZAP 7 (Stratagene): 4.2 × 104 recombinants with 66% background - Contaminants in the DNA sample may have inhibited the enzymatic reactions, though the sucrose gradient and organic extractions may have removed them. Since the DNA sample was precious, an effort was made to “fix” the ends for cloning:
- Re-Blunt DNA
- 1. Pool all left over DNA that was not ligated to the lambda arms (Fractions 1-7) and add H2O to a final volume of 12 μl. Then add:
- 143 μl H2O
- 20 μl 10X Buffer 2 (from Stratagene=s cDNA Synthesis Kit)
- 23 μl Blunting dNTP (from Stratagene=s cDNA Synthesis Kit)
- 2.0 μl Pfu (from Stratagene”s cDNA Synthesis
- 2. Incubate 72° C., 30 minutes.
- 3. Phenol/chloroform extract once.
- 4. Chloroform extract once.
- 5. Add 20 μL 3M NaOAc and 400 μl ice cold ethanol to precipitate.
- 6. Place at −20° C., overnight.
- 7. Spin in microfuge, high speed, 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry.
- (Do NOT Methylate DNA since it was already methylated in the first round of processing)
-
Adaptor Ligation 1. Gently resuspend DNA in 8 Ill EcoR I adaptors (from Stratagene's cDNA Synthesis Kit). 2. Add: 1.0 μl 10X Ligation Buffer 1.0 μl 10 mM rATP 1.0 μl T4 DNA Ligase (4 Wu/μl) 3. Incubate 4° C., 2 days. - (Do NOT cutback since using ADAPTORS this time. Instead, need to phosphorylate)
- Phosphorylate Adaptors
- 1. Heat kill ligation reaction 70° C., 30 minutes.
- Add:
- 1.0 μl 10X Ligation Buffer
- 2.0 μl 10 mM rATF
- 6.0 μl H2O
- 1.0 μl PNK (from Stratagene's cDNA Synthesis Kit).
- 2. Incubate 37° C., 30 minutes.
- 3. Add 31 μl H2O and 5 μl 10X STE.
- 4. Size fractionate on a Sephacryl S-500 spin column (pool fractuions 1-3).
- 5. Phenol/chloroform extract once.
- 6. Chloroform extract once.
- 7. Add ice cold ethanol to precipitate.
- 8. Place on ice, 10 minutes.
- 9. Spin in microfuge, high speed, 30 minutes.
- 10. Wash with 1 ml 70% ethanol.
- 11. Spin in microfuge, high speed, 10 minutes and dry.
- 12. Resuspend in 10.5 μl TE buffer.
- Do not plate assay. Instead, ligate directly to arms as above escept use 2.5 μl of DNA and no water.
- Package and titer as above.
gtll: 2.5 × 106 recombinants with 2.5% background ZAP 7 (Stratagene): 9.6 × 105 recombinants with 0% background - Amplification of Libraries (5.0×105 recombinants from each library)
- 1. Add 3.0 ml host cells (OD660=1.0) to two 50 ml conical tube.
- 2. Inoculate with 2.5×105 pfu per conical tube.
- 3. Incubate 37° C., 20 minutes.
- 4. Add top agar to each tube to a final volume of 45 ml.
- 5. Plate the tube across five 150 mm plates.
- 6. Incubate 37° C., 6-8 hours or until plaques are about pin-head in size.
- 7. Overlay with 8-10 ml SM Buffer and place at 4° C. overnight (with gentle rocking if possible).
- Harvest Phage
- 1. Recover phage suspension by pouring the SM buffer off each plate into a 50-ml conical tube.
- 2. Add 3 ml chloroform, shake vigorously and incubate at room temperature, 15 minutes.
- 3. Centrifuge at 2K rpm, 10 minutes to remove cell debris.
- 4. Pour supernatant into a sterile flask, add 500 pI chloroform.
- 5. Store at 4° C.
- Titer Amplified Library
- 1. Make serial dilutions:
- 10−5=1 μl amplified phage in 1 ml SM Buffer
- 10−6=1 μl of the 10−3 dilution in 1 ml SM Buffer
- 2. Add 200 μl host (in 10 mM MgSO4) to two tubes
- 3. Inoculate one with 10 μl 10−6 dilution (10−5).
- 4. Inoculate the other with 1 μl 10−6 dilution (10−6).
- 5. Incubate 37° C., 15 minutes.
- 6. Add about 3 ml 48° C. top agar.
- [50 ml stock containing 150 μl 1PTG (0.5M) and 375 μl X-GAL (350 mg/ml)]
- 7. Plate on 100 mm plates and incubate 37° C., overnight
- 8. Results:
gtll: 1.7 × 1011/ml ZAP7 (Stratagene): 2.0 × 1010/ml - The following is a representative example of a procedure for screening an expression library prepared in accordance with Example 1. In the following, the chemical characteristic Tiers are as follows:
Tier 1: Hydrolase Tier 2: Amide, Ester and Acetal - Tier 3: Divisions and subdivisions are based upon the differences between individual substrates which are covalently attached to the functionality of
Tier 2 undergoing reaction; as well as substrate specificity. - Tier 4: The two possible enantiomeric products which the protein, e.g. enzyme, may produce from a substrate.
- Although the following example is specifically directed to the above mentioned tiers, the general procedures for testing for various chemical characteristics is generally applicable to substrates other than those specifically referred to in this Example.
- Screening for Tier 1-hydrolase; Tier 2-amide. Plates of the library prepared as described in Example 1 are used to multiply inoculate a single plate containing 200 μl of LB Amp/Meth, glycerol in each well. This step is performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach, water, isopropanol, air-dry sterilization cycle between each inoculation. The single plate is grown for 2 h at 37° C. and is then used to inoculate two white 96-well Dynatech microtiter daughter plates containing 250 μl of LB Arnp/Meth, glycerol in each well. The original single plate is incubated at 37° C. for 18 h, then stored at 80° C. The two condensed daughter plates are incubated at 37° C. also for 18 h. The condensed daughter plates are then heated at 70° C. for 45 min. to kill the cells and inactivate the hostE. coli proteins, e.g. enzymes. A stock solution of 5 mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl cournarin (MuPheAFC, the ‘substrate’) in DMSO is diluted to 600 μM with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/ml of the detergent dodecyl maltoside.
- Fifty μl of the 600 μM MuPheAFC solution is added to each of the wells of the white condensed plates with one 100 μl mix cycle using the Biomek to yield a final concentration of substrate of ˜100 μM. The fluorescence values are recorded (excitation=400 nm, emission=505 nm) on a plate reading fluorometer immediately after addition of the substrate (t=O). The plate is incubated at 70° C. for 100 min, then allowed to cool to ambient temperature for 15 additional minutes. The fluorescence values are recorded again (t=100). The values at t=0 are subtracted from the values at t=100 to determine if an active clone is present.
- The data will indicate whether one of the clones in a particular well is hydrolyzing the substrate. In order to determine the individual clone which carries the activity, the source library plates are thawed and the individual clones are used to singly inoculate a new plate containing LB Amp/Meth, glycerol. As above, the plate is incubated at 37° C. to grow the cells, heated at 70° C. to inactivate the host proteins, e.g. enzymes, and 50 μl of 600 μM MuPheAFC is added using the Biomek. Additionally three other substrates are tested. They are methyl umbelliferone heptanoate, the CBZ-arginine rhodamine derivative, and fluorescein-conjugated casein (˜3.2 mol fluorescein per mol of casein).
- The umbelliferone and rhodamine are added as 600 μM stock solutions in 50 μl of Hepes buffer. The fluorescein-conjugated casein is also added in 50 μl at a stock concentration of 20 and 200 mg/ml. After addition of the substrates the t=0 fluorescence values are recorded, the plate is incubated at 70° C., and the t=100 min. values are recorded as above.
- These data indicate which plate the active clone is in, where the arginine rhodamine derivative is also turned over by this activity, but the lipase substrate. methyl umbelliferone heptanoate, and protein, fluorescein-conjugated casein, do not function as substrates, the
Tier 1 classification is ‘hydrolase’ and theTier 2 classification is amide bond. No cross reactivity should be seen with the Tier 2-ester classification. - As shown in FIG. 1, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as amide may then be tested inTier 3 for various specificities. In FIG. 1, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Table 1 which are used in identifying such specificities ofTier 3. - As shown in FIGS. 2 and 3, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as ester may then be tested inTier 3 for various specificities. In FIGS. 2 and 3, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Tables 3 and 4 which are used in identifying such specificities ofTier 3. In FIGS. 2 and 3, R2 represents the alcohol portion of the ester and R1 represents the acid portion of the ester. - As shown in FIG. 4, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as acetal may then be tested inTier 3 for various specificities. In FIG. 3, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Table 5 which are used in identifying such specificities ofTier 3. -
- R=CH3
- CH2—OH
- CH2—CO2 −
-
- where eep=the enantiomeric excess (ee) of the hydrolyzed product and c=the percent conversion of the reaction. See Wong and Whitesides, Proteins, e.g. enzymes, in Synthetic Organic Chemistry, 1994, Elsevier, Tarrytown, N.Y., pp. 9-12.
- The enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred μl of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 μl of partially or completely purified protein, e.g. enzyme, solution; 50 μl of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, whichever comes first.
- FIG. 5 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample. A stable, large insert DNA library representing picoplankton genomic DNA was prepared as follows.
- Cell collection and preparation of DNA. Agarose plugs containing concentrated picoplankton cells were prepared from samples collected on an oceanographic cruise from Newport, Oreg. to Honolulu, Hi. Seawater (30 liters) was collected in Niskin bottles, screened through 10 μm Nitex, and concentrated by hollow fiber filtration (Amicon DC10) through 30,000 MW cutoff polyfulfone filters. The concentrated bacterioplankton cells were collected on a 0.22 11 m, 47 mm Durapore filter, and resuspended in 1 ml of 2X STE buffer (1M NaCI, 0.1M EDTA, 10 mM Tris, pH 8.0) to a final density of approximately 1×1010 cells per ml. The cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40° C., and then immediately drawn into a 1 ml syringe. The syringe was sealed with parafilm and placed on ice for 10 min. The cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10 mM Tris pH 8.0, 50 mM NaCI, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme) and incubated at 37° C. for one hour. The agarose plug was then transferred to 40 mls of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase K, in 0.5M EDTA), and incubated at 55° C. for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55° C. for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4° C. shipboard for the duration of the oceanographic cruise.
- One slice of an agarose plug (72 μl) prepared from a sample collected off the Oregon coast was dialyzed overnight at 4° C. against 1 ml of buffer A (100 mM NaCI, 10 mM Bis Tris Propane-HCI, 100 μg/ml acetylated BSA: pH 7.0 (@ 25° C.) in a 2 ml microcentrifuge tube. The solution was replaced with 250 μl of fresh buffer A containing 10 mM MgCI2 and 1 mM DTT and incubated on a rocking platform for 1 hr at room temperature. The solution was then changed to 250 μl of the same buffer containing 4U of Sau3A1 (NEB), equilibrated to 37EC in a water bath, and then incubated on a rocking platform in a 37° C. incubator for 45 min. The plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68° C. for 30 min to inactivate the protein, e.g. enzyme, and to melt the agarose. The agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase (Epicentre), respectively, according to the manufacturer's recommendations. Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H20 to a concentration of 2.5 ng/μl for ligation to the
pFOS 1 vector. - PCR amplification results from several of the agarose plugs (data not shown) indicated the presence of significant amounts of archaeal DNA. Quantitative hybridization experiments using rRNA extracted from one sample, collected at 200 m of depth off the Oregon Coast, indicated that planktonic archaea in (this assemblage comprised approximately 4.7% of the total picoplankton biomass (this sample corresponds to “PACI”-200 m in Table 1 of DeLong et al., high abundance of Archaea in Antarctic marine picoplankton,Nature, 371:695-698, 1994). Results from archaeal-biased rDNA PCR amplification performed on agarose plug lysates confirmed the presence of relatively large amounts of archaeal DNA in this sample. Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation. Each 1 ml agarose plug from this site contained approximately 7.5×105 cells, therefore approximately 5.4×105 cells were present in the 72 μl slice used in the preparation of the partially digested DNA.
- Vector arms were prepared from
pFOS 1 as described (Kim et al., Stable propagation of casmid sized human DNA inserts in an F factor based vector, Nucl. Acids Res., 20:10832-10835, 1992). Briefly, the plasmid was completely digested with AstII, dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 35-45 kbp. The partially digested picoplankton DNA, isolated by partial fragment gel electrophoresis (PFGE), was ligated overnight to the PFO SI arms in a 15 μl ligation reaction containing 25 ng each of vector and insert and 1U of T4 DNA ligase (Boehringer-Mannheim). The ligated DNA in four microliters of this reaction was in vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected to E. coli strain DH10B (BRL), and the cells spread onto LBcm15 plates. The resultant fosmid clones were picked into 96-well microliter dishes containing LBcm15 supplemented with 7% glycerol. Recombinant fosmids, each containingcat 40 kb of picoplankton DNA insert, yielded a library of 3,552 fosmid clones, containing approximately 1.4×108 base pairs of cloned DNA. All of the clones examined contained inserts ranging from 38 to 42 kbp. This library was stored frozen at −80° C. for later analysis. - Numerous modifications and variations of the present invention are possible in light of the above teachings; therefore, within the scope of the claims, the invention may be practiced other than as particularly described.
TABLE 1 A2 Fluorescein conjugated casein (3.2 mol fluorescein/mol casein) CBZ-Ala-AMC t-BOC-Ala-Ala-Asp-AMC succinyl-Ala-Gly-Leu-AMC CBZ-Arg-AMC CBZ-Met-AMC morphourea-Phe-AMC t-BOC = t-butoxy carbonyl, CBZ = carbonyl benzyloxy. AMC = 7-amino-4-methyl coumarin AA3 AB3 AC3 AD3 Fluorescein conjugated casein t-BOC-Ala-Ala-Asp-AFC CBZ-Ala-Ala-Lys-AFC succinyl-Ala-Ala-Phe-AFC succinyl-Ala-Gly-Leu-AFC AFC = 7-amino-4-trifluoromethyl coumarin) AE3 Fluorescein conjugated casein AH3 succinyl-Ala-Ala-Phe-AFC CBZ-Phe-AFC CBZ-Trp-AFC AF3 t-BOC-Ala-Ala-Asp-AFC CBZ-Asp-AFC AI3 succinyl-Ala-Gly-Leu-AFC CBZ-Ala-AFC CBZ-Sewr-AFC AG3 CBZ-Ala-Ala-Lys-AFC CBZ-Arg-AFC -
-
-
TABLE 4 G2 β-D-galactose β-D-glucose β-D-glucuronide GB3 β-D-cellotrioside β-D-cellobiopyranoside GC3 β-D-galactose α-D-galactose CD3 β-D-glucose α-D-glucose GE3 β-D-glucuronide GI3 β-D-N,N-diacetylchitobiose GJ3 β-D-fucose α-L-fucose β-L-fucose GK3 β-D-mannose α-D-mannose non-Umbelliferyl substrates GA3 amylose [ polyglucan α 1,4 linkages], amylopectin[ polyglucan branching α 1,6 linkages]GF3 xylan [ poly 1,4-D-xylan]GG3 amylopectin, pullulan GH3 sucrose, fructofuranoside
Claims (22)
1. A method for identifying an enzymatic activity of interest comprising:
culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor eukaryotic organisms; and
detecting the enzymatic activity encoded by the cDNA or genomic DNA fragments.
2. The method of claim 1 , wherein the enzymatic activity is selected from the group consisting of oxidoreductase, transferase, hydrolase, lyase, isomerase, and ligase activity.
3. The method of claim 1 , wherein the donor eukaryotic organisms are microorganisms.
4. The method of claim 3 , wherein the microorganisms are derived from an environmental sample.
5. The method of claim 1 , wherein the microorganisms are a mixed population of uncultured organisms.
6. The method of claim 1 , wherein the organisms are fungi.
7. The method of claim 1 , wherein the organisms are algae.
8. The method of claim 1 , wherein the organisms are protozoan.
9. The method of claim 5 , wherein the organisms are extremophiles.
10. The method of claim 9 , wherein the organisms are thermophiles, hyperthermophiles, psychrophiles, or psychrotrophs.
11. The method of claim 1 , wherein the host cell is a bacterial cell.
12. The method of claim 11 , wherein the bacterial cell is an E. coli, Bacillus, Streptomyces, or Salmonella typhimurium cell.
13. The method of claim 1 , wherein the host cell is a fungal cell.
14. The method of claim 13 , wherein the fungal cell is a yeast cell.
15. The method of claim 1 , wherein the host cell is a Drosophila S2 or a Spodoptera S9 cell.
16. The method of claim 1 , wherein the host cell is an animal cell.
17. The method of claim 16 , wherein the animal cell is a CHO, COS or Bowes melanoma cell.
18. The method of claim 1 , wherein the host organism is a plant cell.
19. A method for identifying an enzymatic activity of interest comprising:
culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor organisms wherein the host cell is a bacterial cell; and
detecting the enzymatic activity encoded by the cDNA or genomic DNA fragments.
20. A method for identifying an enzymatic activity of interest comprising:
culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor organisms, wherein the host cell is a fungal cell; and
detecting the enzymatic activity encoded by the cDNA or genomic DNA fragments.
21. A method for identifying an enzymatic activity of interest comprising:
culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor organisms, wherein the host cell is a plant cell; and
detecting the enzymatic activity encoded by the cDNA or genomic DNA fragments.
22. A method for identifying an enzymatic activity of interest comprising:
culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor organisms wherein the host cell is an animal cell; and
detecting the enzymatic activity encoded by the cDNA or genomic DNA fragments.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/374,576 US20040029173A1 (en) | 1995-07-18 | 2003-02-25 | Protein activity screening of clones having DNA from uncultivated microorganisms |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/503,606 US6004788A (en) | 1995-07-18 | 1995-07-18 | Enzyme kits and libraries |
US56899495A | 1995-12-07 | 1995-12-07 | |
US08/657,409 US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/988,224 US6280926B1 (en) | 1995-07-18 | 1997-12-10 | Gene expression library produced from DNA from uncultivated microorganisms and methods for making the same |
US09/407,525 US6849395B2 (en) | 1995-07-18 | 1999-09-28 | Gene cluster screening of clones having DNA from mixed populations of organisms |
US10/374,576 US20040029173A1 (en) | 1995-07-18 | 2003-02-25 | Protein activity screening of clones having DNA from uncultivated microorganisms |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/407,525 Continuation US6849395B2 (en) | 1995-07-18 | 1999-09-28 | Gene cluster screening of clones having DNA from mixed populations of organisms |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040029173A1 true US20040029173A1 (en) | 2004-02-12 |
Family
ID=27054566
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/657,409 Expired - Lifetime US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/988,224 Expired - Lifetime US6280926B1 (en) | 1995-07-18 | 1997-12-10 | Gene expression library produced from DNA from uncultivated microorganisms and methods for making the same |
US09/407,525 Expired - Fee Related US6849395B2 (en) | 1995-07-18 | 1999-09-28 | Gene cluster screening of clones having DNA from mixed populations of organisms |
US09/713,176 Expired - Lifetime US6528249B1 (en) | 1995-07-18 | 2000-11-14 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US09/875,412 Expired - Fee Related US6677115B2 (en) | 1995-07-18 | 2001-06-06 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US10/364,731 Abandoned US20040005587A1 (en) | 1995-07-18 | 2003-02-10 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US10/374,576 Abandoned US20040029173A1 (en) | 1995-07-18 | 2003-02-25 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US11/247,066 Abandoned US20060068493A1 (en) | 1995-07-18 | 2005-10-11 | Protein activity screening of clones having DNA from uncultivated microorganisms |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/657,409 Expired - Lifetime US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/988,224 Expired - Lifetime US6280926B1 (en) | 1995-07-18 | 1997-12-10 | Gene expression library produced from DNA from uncultivated microorganisms and methods for making the same |
US09/407,525 Expired - Fee Related US6849395B2 (en) | 1995-07-18 | 1999-09-28 | Gene cluster screening of clones having DNA from mixed populations of organisms |
US09/713,176 Expired - Lifetime US6528249B1 (en) | 1995-07-18 | 2000-11-14 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US09/875,412 Expired - Fee Related US6677115B2 (en) | 1995-07-18 | 2001-06-06 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US10/364,731 Abandoned US20040005587A1 (en) | 1995-07-18 | 2003-02-10 | Protein activity screening of clones having DNA from uncultivated microorganisms |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/247,066 Abandoned US20060068493A1 (en) | 1995-07-18 | 2005-10-11 | Protein activity screening of clones having DNA from uncultivated microorganisms |
Country Status (10)
Country | Link |
---|---|
US (8) | US5958672A (en) |
EP (2) | EP0839185B1 (en) |
JP (1) | JP2002514894A (en) |
AT (2) | ATE346148T1 (en) |
AU (1) | AU6547796A (en) |
CA (1) | CA2227342C (en) |
DE (2) | DE69636721T2 (en) |
DK (2) | DK0839185T3 (en) |
ES (1) | ES2277346T3 (en) |
WO (1) | WO1997004077A1 (en) |
Families Citing this family (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495348B1 (en) | 1993-10-07 | 2002-12-17 | Regents Of The University Of Minnesota | Mitomycin biosynthetic gene cluster |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6057103A (en) * | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
US6168919B1 (en) * | 1996-07-17 | 2001-01-02 | Diversa Corporation | Screening methods for enzymes and enzyme kits |
EP0866853B1 (en) * | 1995-12-07 | 2004-03-03 | Diversa Corporation | Method of screening for enzyme activity |
US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
US7018793B1 (en) * | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
US6794127B1 (en) * | 1997-06-16 | 2004-09-21 | Diversa Corporation | Capillary array-based sample screening |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6242211B1 (en) | 1996-04-24 | 2001-06-05 | Terragen Discovery, Inc. | Methods for generating and screening novel metabolic pathways |
US7883872B2 (en) * | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US5811381A (en) * | 1996-10-10 | 1998-09-22 | Mark A. Emalfarb | Cellulase compositions and methods of use |
US6399789B1 (en) * | 1996-12-18 | 2002-06-04 | Kosan Biosciences, Inc. | Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
KR100570935B1 (en) | 1997-01-17 | 2006-04-13 | 맥시겐, 인크. | Evolution of whole cells and organisms by recursive sequence recombination |
US6159687A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US20030013115A1 (en) * | 1997-06-16 | 2003-01-16 | Diversa Corporation, A Delaware Corporation | Capillary array-based sample screening |
US20020015997A1 (en) * | 1997-06-16 | 2002-02-07 | Lafferty William Michael | Capillary array-based sample screening |
WO1999015897A1 (en) * | 1997-09-19 | 1999-04-01 | Chiron Corporation | Subtractive protein screening for gene identification |
US6833242B2 (en) * | 1997-09-23 | 2004-12-21 | California Institute Of Technology | Methods for detecting and sorting polynucleotides based on size |
CA2315819A1 (en) * | 1997-10-15 | 1999-04-22 | Diversa Corporation | Screening for novel compounds which regulate biological interactions |
US6261842B1 (en) * | 1997-10-23 | 2001-07-17 | Wisconsin Alumni Research Foundation | Microorganism genomics, compositions and methods related thereto |
EP1030861A4 (en) | 1997-10-31 | 2001-09-05 | Maxygen Inc | Modification of virus tropism and host range by viral genome shuffling |
KR20010032861A (en) | 1997-12-08 | 2001-04-25 | 캘리포니아 인스티튜트 오브 테크놀로지 | Method for creating polynucleotide and polypeptide sequences |
US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
WO1999057128A1 (en) | 1998-05-01 | 1999-11-11 | Maxygen, Inc. | Optimization of pest resistance genes using dna shuffling |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
US20060242731A1 (en) * | 1998-08-12 | 2006-10-26 | Venkiteswaran Subramanian | DNA shuffling to produce herbicide selective crops |
JP2002522072A (en) | 1998-08-12 | 2002-07-23 | マキシジェン, インコーポレイテッド | DNA shuffling of monooxygenase gene for production of industrial chemicals. |
US20020058249A1 (en) * | 1998-08-12 | 2002-05-16 | Venkiteswaran Subramanian | Dna shuffling to produce herbicide selective crops |
BRPI9914278B1 (en) * | 1998-10-06 | 2016-03-08 | Dyadic Internat Usa Inc | recombinant chrysosporium strain, and method for producing a polypeptide of interest |
AU6510799A (en) | 1998-10-07 | 2000-04-26 | Maxygen, Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
US6368793B1 (en) * | 1998-10-14 | 2002-04-09 | Microgenomics, Inc. | Metabolic selection methods |
WO2000028018A1 (en) | 1998-11-10 | 2000-05-18 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes |
US6438561B1 (en) * | 1998-11-19 | 2002-08-20 | Navigation Technologies Corp. | Method and system for using real-time traffic broadcasts with navigation systems |
DE60042730D1 (en) * | 1999-01-05 | 2009-09-24 | Univ Boston | IMPROVED CLONING PROCESS |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
US6917882B2 (en) * | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
EP2253704B1 (en) | 1999-01-19 | 2015-08-19 | Codexis Mayflower Holdings, LLC | Oligonucleotide mediated nucleic acid recombination |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
JP3399518B2 (en) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Semiconductor structure and method of manufacturing the same |
US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
EP1165775A2 (en) | 1999-03-05 | 2002-01-02 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
WO2001004287A1 (en) * | 1999-07-07 | 2001-01-18 | Maxygen Aps | A method for preparing modified polypeptides |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
US7430477B2 (en) * | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
US20040002147A1 (en) | 1999-12-29 | 2004-01-01 | Desantis Grace | Nitrilases |
SG121902A1 (en) * | 2000-01-11 | 2006-05-26 | Maxygen Inc | Integrated systems for diversity generation and screening |
EP1254212A2 (en) | 2000-02-09 | 2002-11-06 | Genvec, Inc. | Methods of preparing and using a viral vector library |
AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
AU2001287273A1 (en) * | 2000-03-24 | 2001-10-08 | Maxygen, Inc. | Methods for modulating cellular and organismal phenotypes |
KR20020026456A (en) | 2000-04-13 | 2002-04-10 | 에말파브 마크 아론 | High-throughput screening of expressed dna libraries in filamentous fungi |
US20010047029A1 (en) * | 2000-04-26 | 2001-11-29 | Handelsman Jo E. | Triaryl cation antibiotics from environmental DNA |
JP2003534806A (en) * | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | Methods and compositions for targeting adenovirus vectors |
AU2001272978A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
WO2002000897A2 (en) * | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel chimeric promoters |
WO2002000343A2 (en) * | 2000-06-27 | 2002-01-03 | Fluidigm Corporation | A microfluidic design automation method and system |
WO2002004629A2 (en) * | 2000-07-07 | 2002-01-17 | Maxygen, Inc. | Molecular breeding of transposable elements |
US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
AU2001280968A1 (en) * | 2000-07-31 | 2002-02-13 | Menzel, Rolf | Compositions and methods for directed gene assembly |
EP1354031A2 (en) * | 2000-07-31 | 2003-10-22 | Maxygen, Inc. | Nucleotide incorporating enzymes |
US6720168B2 (en) | 2000-08-04 | 2004-04-13 | Genencor International, Inc. | 2,5-DKG permeases |
WO2002012468A2 (en) * | 2000-08-04 | 2002-02-14 | Microgenomics, Inc. | 2,5-dkg permeases |
WO2002016583A2 (en) * | 2000-08-24 | 2002-02-28 | Maxygen, Inc. | Constructs and their use in metabolic pathway engineering |
US20020086313A1 (en) * | 2000-09-25 | 2002-07-04 | Kilbane John J. | Application of bioinformatics for direct study of unculturable microorganisms |
JP2005501217A (en) * | 2000-10-10 | 2005-01-13 | ディベルサ コーポレーション | High-throughput or capillary-based screening for bioactivity or biomolecules |
AU2004260931B9 (en) | 2003-04-29 | 2012-01-19 | E.I. Du Pont De Nemours And Company | Novel glyphosate-N-acetyltransferase (GAT) genes |
US7202070B2 (en) * | 2000-10-31 | 2007-04-10 | Biocatalytics, Inc. | Method for reductive amination of a ketone using a mutated enzyme |
DE10062086A1 (en) * | 2000-12-13 | 2002-07-04 | Wella Ag | Agent and method of dyeing keratin fibers |
US8008459B2 (en) * | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
US7838287B2 (en) * | 2001-01-25 | 2010-11-23 | Evolva Sa | Library of a collection of cells |
US6960437B2 (en) | 2001-04-06 | 2005-11-01 | California Institute Of Technology | Nucleic acid amplification utilizing microfluidic devices |
WO2002086075A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
DK2327766T3 (en) | 2001-06-21 | 2016-03-07 | Basf Enzymes Llc | nitrilases |
EP1578987A2 (en) * | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
US7229811B2 (en) * | 2001-08-03 | 2007-06-12 | Genencor International, Inc. | 2,5-diketo-D-gluconic acid (2,5-DKG) permeases |
US20070298474A1 (en) * | 2001-08-03 | 2007-12-27 | Manoj Kumar | Enhanced 2-Keto-L-Gulonic acid production |
GB0125043D0 (en) * | 2001-10-17 | 2001-12-12 | Biotica Tech Ltd | Production, detection and use of transformant cells |
US6768476B2 (en) * | 2001-12-05 | 2004-07-27 | Etenna Corporation | Capacitively-loaded bent-wire monopole on an artificial magnetic conductor |
DE10163748A1 (en) * | 2001-12-21 | 2003-07-17 | Henkel Kgaa | New glycosyl hydrolases |
EP1472349B1 (en) * | 2002-01-25 | 2008-10-29 | Evolva AG | Methods for multiple parameter screening and evolution of cells to produce small molecules with multiple functionalities |
AU2002306484A1 (en) | 2002-02-13 | 2003-09-04 | Dow Global Technologies Inc. | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
US20030166010A1 (en) * | 2002-02-25 | 2003-09-04 | Affholter Joseph A. | Custom ligand design for biomolecular filtration and purification for bioseperation |
JP2005521425A (en) * | 2002-04-01 | 2005-07-21 | フルイディグム コーポレイション | Microfluidic particle analysis system |
US7312085B2 (en) * | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
CN102174546A (en) | 2002-04-19 | 2011-09-07 | 维莱尼姆公司 | Phospholipases, nucleic acids encoding them and methods for making and using them |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
EP2314698A1 (en) | 2002-06-14 | 2011-04-27 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
JP2005531001A (en) * | 2002-06-24 | 2005-10-13 | フルイディグム コーポレイション | Recirculating fluid network and use thereof |
EP1529110B1 (en) * | 2002-08-01 | 2011-10-05 | Evolva Ltd. | Methods of mixing large numbers of heterologous genes |
BR0313281A (en) | 2002-08-06 | 2007-07-24 | Verdia Inc | ap1 amine oxidase variants |
ATE471981T1 (en) * | 2002-08-20 | 2010-07-15 | B R A I N Biotechnology Res An | ISOLATION AND CLONING OF DNA FROM UNCULTIVATED ORGANISMS |
US7143785B2 (en) * | 2002-09-25 | 2006-12-05 | California Institute Of Technology | Microfluidic large scale integration |
EP1546412B1 (en) | 2002-10-02 | 2014-05-21 | California Institute Of Technology | Microfluidic nucleic acid analysis |
DK1578949T3 (en) | 2002-10-16 | 2009-07-27 | Scripps Research Inst | Site-specific uptake of keto-amino acids in proteins |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP3023498B1 (en) | 2003-03-06 | 2018-11-28 | BASF Enzymes LLC | Amylases, nucleic acids encoding them and methods for making and using them |
DK2853593T3 (en) | 2003-03-07 | 2018-01-08 | Dsm Ip Assets Bv | Hydrolases, nucleic acids encoding them, and processes for their preparation and use |
DK1613733T3 (en) | 2003-04-04 | 2015-08-31 | Basf Enzymes Llc | PEKTATLYASER, nucleic acids encoding them, and methods for making and using the |
BRPI0412279A (en) | 2003-07-02 | 2006-09-19 | Diversa Corp | glucanases, nucleic acids encoding the same and methods for preparing and applying them |
WO2005012550A2 (en) * | 2003-07-31 | 2005-02-10 | Diversa Corporation | Screening methods and libraries of trace amounts of dna from uncultivated microorganisms |
EP1668113B1 (en) | 2003-08-11 | 2013-06-19 | Verenium Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
US20060094033A1 (en) * | 2004-05-21 | 2006-05-04 | Carl Abulencia | Screening methods and libraries of trace amounts of DNA from uncultivated microorganisms |
EA013993B1 (en) | 2004-06-16 | 2010-08-30 | Верениум Корпорейшн | Compositions and methods for enzymatic de-colorization of chlorophyll |
US20050282155A1 (en) * | 2004-06-17 | 2005-12-22 | Lucigen Corporation | Viral libraries from uncultivated viruses and polypeptides produced therefrom |
ES2371764T3 (en) * | 2004-08-03 | 2012-01-09 | Novartis Vaccines And Diagnostics, Inc. | PROCEDURE FOR OBTAINING NUCLEIC ACIDS THROUGH MICROBIAL SAMPLE LISIS. |
DE102004046116A1 (en) * | 2004-09-23 | 2006-04-06 | Henkel Kgaa | Pullulanases from psychrophilic organisms |
CA2583735A1 (en) | 2004-10-27 | 2006-10-19 | The Scripps Research Institute | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
WO2006053131A1 (en) | 2004-11-11 | 2006-05-18 | Modular Genetics, Inc. | Ladder assembly and system for generating diversity |
CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
CA2611859C (en) | 2005-03-15 | 2015-03-31 | Verenium Corporation | Cellulases, nucleic acids encoding them and methods for making and using them |
PL2314623T3 (en) | 2005-06-21 | 2012-11-30 | Xoma Us Llc | IL-1beta binding antibodies and fragments thereof |
US20090324574A1 (en) | 2006-02-02 | 2009-12-31 | Verenium Corporation | Esterases and Related Nucleic Acids and Methods |
WO2007092475A2 (en) * | 2006-02-06 | 2007-08-16 | Franklin And Marshall College | Site-specific incorporation of fluorinated amino acids into proteins |
MY160772A (en) | 2006-02-10 | 2017-03-15 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
PL1989302T3 (en) | 2006-02-14 | 2019-03-29 | Bp Corp North America Inc | Xylanases, nucleic acids encoding them and methods for making and using them |
EP3153580A3 (en) | 2006-03-07 | 2017-04-19 | BASF Enzymes LLC | Aldolases, nucleic acids encoding them and methods for making and using them |
EP2112227B1 (en) * | 2006-03-07 | 2013-05-15 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
WO2007136833A2 (en) * | 2006-05-19 | 2007-11-29 | Codon Devices, Inc. | Methods and compositions for aptamer production and uses thereof |
AU2007356171B8 (en) | 2006-08-04 | 2014-01-16 | Bp Corporation North America Inc. | Glucanases, nucleic acids encoding them, and methods for making and using them |
CN101558154B (en) | 2006-09-21 | 2016-02-24 | 帝斯曼知识产权资产管理有限公司 | Phospholipid hydrolase, encode their nucleic acid and methods for making and using same thereof |
MX2009003032A (en) | 2006-09-21 | 2009-11-18 | Verenium Corp | Phytases, nucleic acids encoding them and methods for making and using them. |
US9862956B2 (en) | 2006-12-10 | 2018-01-09 | Danisco Us Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
US8680252B2 (en) | 2006-12-10 | 2014-03-25 | Dyadic International (Usa), Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
PL2479267T3 (en) | 2006-12-21 | 2017-06-30 | Basf Enzymes Llc | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
BRPI0807132A2 (en) | 2007-01-30 | 2018-12-04 | Syngenta Participations Ag | enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof |
EP2115153B1 (en) | 2007-03-01 | 2013-06-05 | BP Corporation North America Inc. | Nitrilases, nucleic acids encoding them and methods for making and using them |
CA2736661A1 (en) * | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
NZ601191A (en) | 2007-10-03 | 2014-01-31 | Verenium Corp | Xylanases, nucleic acids encoding them and methods for making and using them |
US8541220B2 (en) | 2008-01-03 | 2013-09-24 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
EP2865750A3 (en) | 2008-01-03 | 2015-08-05 | BASF Enzymes LLC | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
CN102224238B (en) | 2008-09-26 | 2015-06-10 | Ambrx公司 | Non-natural amino acid replication-dependent microorganisms and vaccines |
JP2012527247A (en) | 2009-05-21 | 2012-11-08 | ヴェレニウム コーポレイション | Phytase, nucleic acid encoding phytase and method for producing and using the same |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
WO2012021797A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeting sequences of interest to the chloroplast |
WO2012106579A1 (en) | 2011-02-03 | 2012-08-09 | Bristol-Myers Squibb Company | Amino acid dehydrogenase and its use in preparing amino acids from keto acids |
CN104540939A (en) | 2012-03-16 | 2015-04-22 | Bp北美公司 | Polypeptides having endoglucanase activity |
WO2013166113A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
CA2879680A1 (en) | 2012-07-24 | 2014-01-30 | Bp Corporation North America Inc. | Xylose isomerases and their uses |
EP2970935A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
CA2905595A1 (en) | 2013-03-14 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
US10345289B2 (en) * | 2013-04-18 | 2019-07-09 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for analyzing a target material |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
US11608516B2 (en) | 2015-04-15 | 2023-03-21 | Ecolab Usa Inc. | Method for determination of diversity and viability thresholds used to assess microorganisms in process samples |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654150A (en) * | 1995-06-07 | 1997-08-05 | President And Fellows Of Harvard College | Method of expression cloning |
US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
US5824485A (en) * | 1995-04-24 | 1998-10-20 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675285A (en) * | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
JPH02238882A (en) * | 1989-03-13 | 1990-09-21 | Takara Shuzo Co Ltd | Synthesis of cdna and kit therefor |
AU7791991A (en) * | 1990-04-24 | 1991-11-11 | Stratagene | Methods for phenotype creation from multiple gene populations |
US5352778A (en) * | 1990-04-26 | 1994-10-04 | New England Biolabs, Inc. | Recombinant thermostable DNA polymerase from archaebacteria |
WO1992011321A2 (en) | 1990-12-18 | 1992-07-09 | Elf France | Bitumen/polymer component giving bitumen/polymer compositions with very low heat sensitivity for use in surfacing |
US5316935A (en) * | 1992-04-06 | 1994-05-31 | California Institute Of Technology | Subtilisin variants suitable for hydrolysis and synthesis in organic media |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6033883A (en) | 1996-12-18 | 2000-03-07 | Kosan Biosciences, Inc. | Production of polyketides in bacteria and yeast |
US6117659A (en) | 1997-04-30 | 2000-09-12 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
US6090601A (en) | 1998-01-23 | 2000-07-18 | Kosan Bioscience | Sorangium polyketide synthase |
US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
US6177262B1 (en) | 1998-09-22 | 2001-01-23 | Kosan Biosciences, Inc. | Recombinant host cells for the production of polyketides |
-
1996
- 1996-06-03 US US08/657,409 patent/US5958672A/en not_active Expired - Lifetime
- 1996-07-17 JP JP50682997A patent/JP2002514894A/en not_active Ceased
- 1996-07-17 DE DE69636721T patent/DE69636721T2/en not_active Expired - Lifetime
- 1996-07-17 EP EP96925351A patent/EP0839185B1/en not_active Expired - Lifetime
- 1996-07-17 ES ES96925351T patent/ES2277346T3/en not_active Expired - Lifetime
- 1996-07-17 DE DE69638168T patent/DE69638168D1/en not_active Expired - Lifetime
- 1996-07-17 WO PCT/US1996/011854 patent/WO1997004077A1/en active IP Right Grant
- 1996-07-17 DK DK96925351T patent/DK0839185T3/en active
- 1996-07-17 AT AT96925351T patent/ATE346148T1/en not_active IP Right Cessation
- 1996-07-17 EP EP06009151A patent/EP1696025B1/en not_active Expired - Lifetime
- 1996-07-17 AT AT06009151T patent/ATE465246T1/en not_active IP Right Cessation
- 1996-07-17 CA CA2227342A patent/CA2227342C/en not_active Expired - Lifetime
- 1996-07-17 DK DK06009151.9T patent/DK1696025T3/en active
- 1996-07-17 AU AU65477/96A patent/AU6547796A/en not_active Abandoned
-
1997
- 1997-12-10 US US08/988,224 patent/US6280926B1/en not_active Expired - Lifetime
-
1999
- 1999-09-28 US US09/407,525 patent/US6849395B2/en not_active Expired - Fee Related
-
2000
- 2000-11-14 US US09/713,176 patent/US6528249B1/en not_active Expired - Lifetime
-
2001
- 2001-06-06 US US09/875,412 patent/US6677115B2/en not_active Expired - Fee Related
-
2003
- 2003-02-10 US US10/364,731 patent/US20040005587A1/en not_active Abandoned
- 2003-02-25 US US10/374,576 patent/US20040029173A1/en not_active Abandoned
-
2005
- 2005-10-11 US US11/247,066 patent/US20060068493A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824485A (en) * | 1995-04-24 | 1998-10-20 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
US5654150A (en) * | 1995-06-07 | 1997-08-05 | President And Fellows Of Harvard College | Method of expression cloning |
US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
Also Published As
Publication number | Publication date |
---|---|
DE69638168D1 (en) | 2010-06-02 |
ATE346148T1 (en) | 2006-12-15 |
EP1696025B1 (en) | 2010-04-21 |
CA2227342C (en) | 2011-03-29 |
US6528249B1 (en) | 2003-03-04 |
CA2227342A1 (en) | 1997-02-06 |
EP0839185B1 (en) | 2006-11-22 |
US20020086279A1 (en) | 2002-07-04 |
US5958672A (en) | 1999-09-28 |
DK1696025T3 (en) | 2010-07-19 |
US20020172944A1 (en) | 2002-11-21 |
EP1696025A3 (en) | 2006-09-13 |
US20040005587A1 (en) | 2004-01-08 |
DE69636721T2 (en) | 2008-01-24 |
AU6547796A (en) | 1997-02-18 |
EP0839185A1 (en) | 1998-05-06 |
US6849395B2 (en) | 2005-02-01 |
ES2277346T3 (en) | 2007-07-01 |
DE69636721D1 (en) | 2007-01-04 |
US6677115B2 (en) | 2004-01-13 |
EP0839185A4 (en) | 2002-10-30 |
US20060068493A1 (en) | 2006-03-30 |
JP2002514894A (en) | 2002-05-21 |
ATE465246T1 (en) | 2010-05-15 |
WO1997004077A1 (en) | 1997-02-06 |
EP1696025A2 (en) | 2006-08-30 |
DK0839185T3 (en) | 2007-02-19 |
US6280926B1 (en) | 2001-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6677115B2 (en) | Protein activity screening of clones having DNA from uncultivated microorganisms | |
US6168919B1 (en) | Screening methods for enzymes and enzyme kits | |
US6054267A (en) | Method for screening for enzyme activity | |
US6344328B1 (en) | Method for screening for enzyme activity | |
US6030779A (en) | Screening for novel bioactivities | |
US6656677B2 (en) | Enzyme kits and libraries | |
AU720334B2 (en) | Method of screening for enzyme activity | |
US6368798B1 (en) | Screening for novel bioactivities | |
US6790605B1 (en) | Methods for obtaining a desired bioactivity or biomolecule using DNA libraries from an environmental source | |
US8476011B1 (en) | Construction and use of catalogued nucleic acid libraries that contain advantageously adjusted representations of defined components | |
AU767618B2 (en) | Screening methods for enzymes and enzyme kits | |
AU756201B2 (en) | Method of screening for enzyme activity | |
US20020164580A1 (en) | Combinatorial screening of mixed populations of organisms | |
AU2007202329A1 (en) | Method of screening for enzyme activity | |
AU2003200812A2 (en) | Method of screening for enzyme activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |